Pinpin Lin

Publications (2)9.71 Total impact

• Article: Meta- and pooled analysis of GSTP1 polymorphism and lung cancer: a HuGE-GSEC review.

  Michele L Cote, Wei Chen, Daryn W Smith, Simone Benhamou, Christine Bouchardy, Dorota Butkiewicz, Kwun M Fong, Manuel Gené, Ari Hirvonen, Chikako Kiyohara, [......], Joachim Schneider, Ann G Schwartz, Mette Sorensen, Jordi To-Figueras, Shinkan Tokudome, Yuepu Pu, Ping Yang, Angela S Wenzlaff, Harriet Wikman, Emanuela Taioli
  [show abstract] [hide abstract]
  ABSTRACT: Lung cancer is the most common cancer worldwide. Polymorphisms in genes associated with carcinogen metabolism may modulate risk of disease. Glutathione S-transferase pi (GSTP1) detoxifies polycyclic aromatic hydrocarbons found in cigarette smoke and is the most highly expressed glutathione S-transferase in lung tissue. A polymorphism in the GSTP1 gene, an A-to-G transition in exon 5 (Ile105Val, 313A --> 313G), results in lower activity among individuals who carry the valine allele. The authors present a meta- and a pooled analysis of case-control studies that examined the association between this polymorphism in GSTP1 and lung cancer risk (27 studies, 8,322 cases and 8,844 controls and 15 studies, 4,282 cases and 5,032 controls, respectively). Overall, the meta-analysis found no significant association between lung cancer risk and the GSTP1 exon 5 polymorphism. In the pooled analysis, there was an overall association (odds ratio = 1.11, 95% confidence interval: 1.03, 1.21) between lung cancer and carriage of the GSTP1 Val/Val or Ile/Val genotype compared with those carrying the Ile/Ile genotype. Increased risk varied by histologic type in Asians. There appears to be evidence for interaction between amount of smoking, the GSTP1 exon 5 polymorphism, and risk of lung cancer in whites.
  American journal of epidemiology 03/2009; 169(7):802-14. · 5.59 Impact Factor
• Article: CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations.

  Kyoung-Mu Lee, Daehee Kang, Margie L Clapper, Magnus Ingelman-Sundberg, Masko Ono-Kihara, Chikako Kiyohara, Shen Min, Qing Lan, Loic Le Marchand, Pinpin Lin, Maria Li Lung, Hatice Pinarbasi, Paola Pisani, Petcharin Srivatanakul, Adeline Seow, Haruhiko Sugimura, Shinkan Tokudome, Jun Yokota, Emanuela Taioli
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate the roles of CYP1A1 polymorphisms [Ile 462Val and T 6235C (MspI)] and deletion of GSTM1 and GSTT1 in lung cancer development in Asian populations, a pooled analysis was conducted on 13 existing studies included in Genetic Susceptibility to Environmental Carcinogenesis database. This pooled analysis included 1,971 cases and 2,130 controls. Lung cancer risk was estimated as odds ratios (OR) and 95% confidence intervals (95% CI) using unconditional logistic regression model adjusting for age, sex, and pack-year. The CYP1A1 6235C variant was associated with squamous cell lung cancer (TC versus TT: OR, 1.42; 95% CI, 0.96-2.09; CC versus TT: OR, 1.97; 95% CI, 1.26-3.07; P trend = 0.003). In haplotype analysis, 462Val-6235T and Ile-C haplotypes were associated with lung cancer risk with reference to the Ile-T haplotype (OR, 3.41; 95% CI, 1.78-6.53 and OR, 1.39; 95% CI, 1.12-1.71, respectively). The GSTM1-null genotype increased squamous cell lung cancer risk (OR, 1.36; 95% CI, 1.05-1.77). When the interaction was evaluated with smoking, increasing trend of lung cancer risk as pack-year increased was stronger among those with the CYP1A1 6235 TC/CC genotype compared with those with TT genotype (P interaction = 0.001) and with the GSTM1-null genotype compared with the present type (Pinteraction = 0.08, when no genotype effect with no exposure was assumed). These results suggest that genetic polymorphisms in CYP1A1 and GSTM1 are associated with lung cancer risk in Asian populations. However, further investigation is warranted considering the relatively small sample size when subgroup analyses were done and the lack of environmental exposure data other than smoking.
  Cancer Epidemiology Biomarkers &amp Prevention 06/2008; 17(5):1120-6. · 4.12 Impact Factor